Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation at the H.C. Wainwright Global Life Sciences Conference. The Company will be featured as a presenting company. The conference will be held on a virtual platform from March 9-10, 2021.
As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link to register for the conference: www.hcwevents.com/globalconference.
The conference will feature over 400 corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Global Life Sciences Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the field of the development of medicines for treatment of blood and autoimmune diseases. "
https://www.share-talk.com/dr-vladislav-sandler-ceo-co-founder-of-hemogenyx-pharmaceuticals-hemo-l-interview/
As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link to register for the conference: www.hcwevents.com/globalconference.
The conference will feature over 400 corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Global Life Sciences Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the field of the development of medicines for treatment of blood and autoimmune diseases. "
https://www.share-talk.com/dr-vladislav-sandler-ceo-co-founder-of-hemogenyx-pharmaceuticals-hemo-l-interview/
Show Notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation at the H.C. Wainwright Global Life Sciences Conference. The Company will be featured as a presenting company. The conference will be held on a virtual platform from March 9-10, 2021.
As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link to register for the conference: www.hcwevents.com/globalconference.
The conference will feature over 400 corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Global Life Sciences Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the field of the development of medicines for treatment of blood and autoimmune diseases. "
https://www.share-talk.com/dr-vladislav-sandler-ceo-co-founder-of-hemogenyx-pharmaceuticals-hemo-l-interview/
Listen On
Also Listen
-
Blackbird CEO Ian McDonough sits down with Zak Mir to talk results FY24 and elevate.io milestones achieved
Zak Mir talks to Ian McDonough, CEO of Blackbird, in the wake of the Final Resul -
Zak Mir talks to Alastair Clayton, Executive Chairman of Thor Energy Plc
Zak Mir talks to Alastair Clayton, Executive Chairman, Thor Energy, in the wake -
Zak Mir talks to Harry Baker, Chief Executive of Borders and Southern Petroleum PLC
Zak Mir talks to Harry Baker, CEO of Borders & Southern, after the London-based -
Zak Mir talks to Harry Baker, Chief Executive of Borders and Southern Petroleum PLC
Zak Mir talks to Harry Baker, CEO of Borders & Southern, after the London-based